Last reviewed · How we verify
NCT06812000
Post-stroke Seizure and Epilepsy Following Thrombolytic Therapy
trial in Post-stroke Seizure in 199 participants. Completed in 12 January 2025.
12 January 2025
Quick facts
| Lead sponsor | Mazandaran University of Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 199 |
| Start date | 14 April 2024 |
| Primary completion | 12 January 2025 |
| Estimated completion | 12 January 2025 |
| Sites | 1 location across Iran |
Conditions studied
- Post-stroke Seizure — all drugs for Post-stroke Seizure →
- Post-stroke Epilepsy — all drugs for Post-stroke Epilepsy →
- Thrombolytic (t-PA) Treatment — all drugs for Thrombolytic (t-PA) Treatment →
Sponsor
Mazandaran University of Medical Sciences
Who can join
18 and older, any sex, with Post-stroke Seizure or Post-stroke Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective cohort study was conducted by reviewing the records of consecutive patients referred to Bu Ali Sina Hospital from 2016 to 2023, who were hospitalized with a diagnosis of ischemic stroke. The records of all patients treated with intravenous alteplase during the above period were extracted, and the relevant characteristics were recorded in a questionnaire. In each year, patients with ischemic stroke who were not treated with alteplase but were hospitalized at the Bu Ali Center were selected in a similar number to patients who received alteplase in the same year, and the relevant information was extracted from their records and recorded in a questionnaire. The incidence of post-stroke seizures and epilepsy was determined in both groups, and the factors associated with their incidence were studied and compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06812000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Mazandaran University of Medical Sciences trials
Trials by the same sponsor.
- NCT06737406 — Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart · NA · recruiting
- NCT06653348 — Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke · Phase 2, PHASE3 · recruiting
- NCT07120841 — Nurse Telephone Follow-up for Cardiovascular Patients · NA · completed
- NCT07210450 — Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia · Phase 2, PHASE3 · completed
- NCT05969730 — Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06812000 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mazandaran University of Medical Sciences
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing